The Regulator

28 patients: that is how many federal reviewers found may not yet have died when Kentucky’s organ procurement organization began preparing them for donation, the finding behind only the second time the federal government has ever decertified an organ procurement organization (OPO). The Department of Health and Human Services announced August 5, 2026 that it is decertifying Network for Hope, the federally designated OPO serving Kentucky and parts of Indiana, Ohio and West Virginia, after a Health Resources and Services Administration review of 351 cases from 2021 through 2024 in which organ donation was authorized but not completed found inadequate neurological assessments, poor coordination with medical teams and questionable consent practices, including at least 28 cases where reviewers found the patient may not yet have been deceased when the donation process began. In one 2021 case cited in the review, the organization allegedly pressured hospital staff to keep preparing a man who had overdosed for organ donation even as he showed signs of regaining consciousness; the procurement did not proceed and the man survived. Network for Hope says it will appeal; under federal rules it has 15 business days to request reconsideration and then a hearing if the Centers for Medicare and Medicaid Services upholds the finding, and its four-state service area cannot open to competing OPOs until that process concludes. Confidence: Medium. HHS’s own press release states the decertification and the department’s rationale, but this run could not independently retrieve the full text of HHS’s posting, which returned an access error; the case counts and example are corroborated by trade-press reporting citing the federal review directly. Sources: HHS Decertifies Kentucky Organ Procurement Organization to Protect Patients, Restore Trust, U.S. Department of Health and Human Services, HHS moves to decertify organ procurement group over patient safety failures, Healthcare Dive.

90 to 6: that is the lopsided Senate vote that just funded the federal government, including WIC, through December 11, punting the next shutdown fight past the midterms. The Senate passed H.R. 6500, a continuing resolution keeping federal agencies funded at current levels through December 11, 2026, in a 90-6 vote early Saturday, August 8, after days of Republican infighting over a White House-backed provision delaying a ban on hemp-derived THC products from November 12 to December 11; senators tabled an amendment to strip that delay 61-32 before final passage. The measure also extends funding for the Women, Infants and Children nutrition program, surface transportation programs and the Disaster Relief Fund, and now goes to the House, which passed a different, more bare-bones stopgap before its August recess that Democrats have largely opposed. Confidence: Medium. This run could not independently retrieve the bill text on Congress.gov or the official Senate roll call, both of which returned access errors, but the vote count, date and provisions are corroborated by Senate Democratic leadership’s own daily record and wire reporting. Sources: Wrap Up for Friday, August 7 and Saturday, August 8, 2026, Senate Democratic Leadership, Funding patch passes Senate to head off fall shutdown, Roll Call.

One year: that is how long HRSA’s rebate-based overhaul of the 340B drug discount program would have left to live under a new Senate bill, a direct threat to the pilot this newsletter reported was headed for an August 24 manufacturer opt-in deadline. Six senators from both parties, John Boozman, Jerry Moran, Tammy Baldwin, Shelley Moore Capito, Tim Kaine and John Hickenlooper, introduced the SUSTAIN 340B Act on August 5, 2026, which would terminate the Health Resources and Services Administration’s 340B Rebate Model Pilot within one year of enactment and replace it with an independent, third-party data clearinghouse to prevent duplicate discounts, while codifying contract pharmacy use, tightening the 340B patient definition and requiring covered entities to post standardized financial-assistance policies for patients at or below 200 percent of the federal poverty level. The bill authorizes $3 million a year for five years for program oversight and $9 million a year for four years for implementation, and would let HHS remove noncompliant covered entities from the program entirely. Confidence: High. The lead sponsor’s own press release states the bill’s provisions, sponsors and appropriations directly. Sources: Senate 340B Bipartisan Working Group Introduces Comprehensive 340B Reform Legislation, Senator John Boozman.

Two: that is how many times the Food and Drug Administration (FDA) rejected this melanoma drug before approving it this week, a reversal that gives patients the first oncolytic virus therapy ever cleared for the disease. The FDA granted accelerated approval August 6, 2026 to Tudriqev (vusolimogene oderparepvec), a genetically modified herpes-virus therapy from Replimune Group that replicates inside tumors to trigger cell death and recruit immune cells, for use with the checkpoint inhibitor nivolumab in adults with advanced melanoma that progressed after anti-PD-1 treatment; the agency had issued complete response letters in July 2025 and April 2026 citing the single-arm design of the IGNYTE trial before an FDA advisory committee voted 10-3 in July that the data showed a clinically meaningful benefit. In the 91-patient efficacy population, the combination produced a 24.2 percent objective response rate with a median response duration of 14.1 months in patients who had exhausted standard options. Confidence: High. Replimune’s own press release states the approval date, trial data and regulatory history directly. Sources: Replimune Announces FDA Accelerated Approval of TUDRIQEV in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma, Replimune Group.

88 million dollars: that is what a federal jury says Medtronic owes one Alabama couple over a hernia mesh implant, the largest compensatory verdict in 15 years of mesh litigation and the first of more than 2,400 cases to reach trial. A jury in the U.S. District Court for the District of Massachusetts, where the multidistrict litigation over Medtronic’s Covidien-brand Symbotex hernia mesh is centralized before Judge Patti Saris, returned the verdict August 4, 2026 after a three-week trial, awarding Larry Patterson $77 million and his wife Tammy Patterson $11 million for loss of consortium after finding Covidien failed to adequately warn that the mesh’s protective coating could dissolve faster than expected, allowing it to adhere to Patterson’s bowel and require additional surgery. Jurors awarded no punitive damages and did not find Covidien committed fraud; Medtronic has said it will challenge the verdict in post-trial motions and on appeal. Confidence: High. The verdict amount, court, judge and case outcome are corroborated directly across multiple wire and legal-trade reports of the jury’s finding. Sources: US jury says Medtronic owes $88 million in first case to go to trial over Covidien’s hernia mesh, U.S. News & World Report, Covidien Hernia Mesh Lawsuit Payout of $88M Awarded in First MDL Bellwether Trial, AboutLawsuits.com.